Indivior to cancel London Stock Exchange secondary listing, maintain Nasdaq primary listing

Indivior Pharmaceuticals, Inc.

London delisting effective July 25, 2025; last trading on LSE July 24, 2025.
Over 80% of net revenue from US; 75% of trading volume on Nasdaq; over 70% of shareholders by value US-based.
Nasdaq listing under INDV unaffected; direct holders and DTC broker/custodian holders unaffected.
Holders of UK Depositary Interests and Corporate Sponsored Nominee facility advised to convert holdings for Nasdaq trading.
UK Takeover Code remains applicable for 2 years after delisting; mandatory offer rules unchanged.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.